Company / Operating Income per Share
Celldex Therapeutics, Inc. Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$4.32
FY2025
5-year range
-$4.32 / -$1.52
FY2021-FY2025
Trend
-46.9%
vs FY2024
Sector context
#147 of 155
Health Care
What the data says
Among 155 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 5% for operating income per share. Operating Income per Share has declined for 4 consecutive years, from $-1.52 in FY2021 to $-4.32 in FY2025.
Based on SEC 10-K filings.
-4.32 in FY2025.
Declined from $-2.77 to $-4.32 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 155This company -$4.32 Sector average $4.18
▼
-203.4% below sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s operating income per share has declined for 4 consecutive years.
- In FY2025, operating income per share decreased 46.9% year-over-year.
- Ranks #147 out of 155 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.32 | -46.9% |
| FY2024 | -$2.94 | -6.3% |
| FY2023 | -$2.77 | -13.3% |
| FY2022 | -$2.44 | -60.1% |
| FY2021 | -$1.52 | +4.7% |
| FY2020 | -$1.60 | +50.7% |
| FY2019 | -$3.24 | +77.5% |
| FY2018 | -$14.39 | -1327.3% |
| FY2017 | -$1.01 | +8.6% |
| FY2016 | -$1.10 | +16.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026